Psychosis Market
Report ID: SQMIG35I3129
Report ID: SQMIG35I3129
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3129 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
143
|Figures:
77
Global Psychosis Market size was valued at USD 12.59 Billion in 2024 and is poised to grow from USD 13.38 Billion in 2025 to USD 21.82 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).
The psychosis market consists of drugs, diagnostic products, and therapies designed to prevent and treat schizophrenia, bipolar disorder, and other psychotic disorders. The importance of this market is linked to the increasing incidence of mental disorders that affect 3% of the world population and bring about billions of dollars in healthcare expenditure. Traditionally, the market consisted primarily of antipsychotics; however, the advent of atypical drugs in the 1990s boosted the demand and opened new perspectives. Modern developments in genetics and neuroimaging allowed for better patient stratification, thus stimulating investments into precision medicine. As a result, the market expanded from an insignificant niche in the 2000s to a multibillion one nowadays.
The other driving factor behind the psychosis market is the incorporation of real-world evidence (RWE) in drug development and payment decision making. Through the collection of data on patient outcomes from EHRs and wearables, clinicians obtain information that reflects the efficacy of treatments in different patient groups. It lowers regulatory risks and incentivizes pharma companies to develop new antipsychotics using different modes, including phosphodiesterase-10 inhibition. In one clinical trial, RWE was used to show better prevention rates of relapse in different settings, which has led to more insurance coverage for the product. The growth of the market is visible through increased partnership deals between biotech companies and manufacturers.
How is AI-driven Diagnostic Automation Influencing the Global Psychosis Market?
AI-assisted diagnostic automation is transforming the market by cutting down the time between symptom occurrence and diagnosis. Machine learning algorithms identify early changes in psychosis by analyzing the speech pattern, gait, and neuroimaging data, enabling timely interventions to prevent full-blown episodes. This approach helps in avoiding hospitalizations and better matching patients with treatments, leading to increased demand for advanced solutions. Moreover, this technology facilitatesthe creation of standardized databases of big data that contribute to drug discovery and development, generating a positive feedback cycle. Increasing number of investors and payers view the use of AI-assisted diagnostics as a cost-effective way of increasing accessibility while sustaining high-quality care, making the market attractive to both legacy players and startups.
Market snapshot - (2026-2033)
Global Market Size
USD 12.59 Billion
Largest Segment
Atypical Antipsychotics (Second Generation)
Fastest Growth
Long-Acting Injectable Antipsychotics (LAI)
Growth Rate
6.3% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global psychosis market is segmented by drug class, disorder type, route of administration, drug type, end user and region. Based on drug class, the market is segmented into Atypical Antipsychotics (Second Generation), Typical Antipsychotics (First Generation) and Long-Acting Injectable Antipsychotics (LAI). Based on disorder type, the market is segmented into Schizophrenia, Schizoaffective Disorder, Bipolar Disorder with Psychotic Features and Delusional Disorders. Based on route of administration, the market is segmented into Oral and Injectable (IM / LAI). Based on drug type, the market is segmented into Branded and Generic. Based on end user, the market is segmented into Hospitals & Psychiatric Clinics, Outpatient Facilities and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Atypical Antipsychotics (Second Generation) is the dominant market segment as healthcare professionals focus on the effectiveness of the treatment of positive and negative symptoms in addition to providing better side effect profiles. The benefit of the drug leads to preference for the agents among healthcare professionals in hospitals as well as outpatient care centers. The lower risk of metabolic disorders and movement disorders further enhances the confidence of physicians leading to dominance of the segment in the psychosis market.
Nevertheless, Long-Acting Injectable Antipsychotics (LAI) is the fastest growing market segment in the psychotic disorder market owing to efforts of adhering to the therapy by reducing pills' burden.
The segment of Schizophrenia is the dominant one as it has the largest share of the patient base, thus receiving heavy research spending and a pipeline of drug candidates. There are substantial healthcare expenditures on chronic management of the condition and relapses, leading to continuous prescription in-patient and out-patient facilities. This results in coverage by payers, addition to formularies, and a demand for existing and novel drugs, thus making the segment of Schizophrenia a key one for the psychosis market.
At the same time, the bipolar disorder with Psychotic Features segment becomes a high growth one as practitioners understand the necessity for mood stabilizers combined with an action against psychosis. The expanded criteria for the diagnosis and treatment lead to the usage of combination therapy, resulting in drug innovation and investment.
To get detailed segments analysis, Request a Free Sample Report
North America boasts an advanced healthcare delivery system, extensive research facilities, and the presence of numerous innovative pharmaceutical companies. Efficient reimbursement models and quick adoption of new treatment methods enable speedy acceptance of innovations. In addition, the regulatory policies of the region are a perfect balance of safety and speed, promoting clinical trials and fast commercialization. There exist excellent collaboration models in the region between academia, biotech companies, and patient advocates, which helps speed up innovation dissemination. Another factor that contributes to North America’s leadership is high awareness and mental health services.
Psychosis Market Dynamics in the U.S. The market dynamics for the psychosis industry are driven by an extensive pipeline of innovative treatments backed by venture capital funding. The integration of health systems and payment models allows for widespread accessibility, with prominent institutions spearheading groundbreaking clinical studies. The intersection of technology, personalized medicine, and a robust payer network ensure a thriving ecosystem that keeps expanding treatment opportunities for those suffering from psychotic illnesses.
Market for Psychosis The Canadian market for psychosis is supported by a health care system that is publicly funded and emphasizes the provision of mental health services that ensure equal access for everyone. Academic and pharmaceutical companies collaborate on research to come up with more innovative drugs. Health care officials within the provinces have prioritized early intervention programs.
The growth of the psychotic diseases market in Europe is driven by the harmonization of regulatory systems that simplify the process of conducting clinical trials and market authorization. Public and private financing of research into neurosciences together with robust health-care reimbursement systems foster the adoption of innovative treatment methods. The patient-centered approach to health care and mental health networks adopted by European countries increases diagnostic and treatment of adherence. Additionally, cooperation between EU countries allows for data exchange and clinical trials.
Germany's Psychosis market is distinguished by an effective universal health care system ensuring extensive insurance cover in the case of psychiatry. The market is also noted for advanced clinical trials as well as strong relations between drug makers and the health insurers, which leads to quick reimbursement of decision-making processes.
Psychosis Market in the United Kingdom is facilitated due to an already well-established NHS, which focuses on the integration of mental health into primary care. Adoption of digital health technology and telepsychiatry brings services to those who are hard-to-reach. Partnerships in academia and government funding for development of therapies make the United Kingdom a rapidly developing market segment.
The Psychosis Market in France enjoys an organized health care system with an emphasis on early diagnosis and care within the community. The establishment of research consortia combining public and private bodies enables translational research, while reimbursement programs at the national level provide incentives for using novel treatments.
The Asia Pacific psychosis market is witnessing growth owing to growing government involvement in mental health reforms and growing insurance coverage for psychiatric disorders. Factors such as increasing urbanization and increased awareness of mental health issues have created the need for new therapies. An increasing number of biotech players in the region, backed by smart investments and talent development, hastened the process of developing new therapies. Clinical networks among different countries have enabled multi-country trials.
The Psychosis Market in Japan is characterized by the country’s aging population, which has an increased interest in mental health care. With strict regulations for drug approval, the rapid introduction of new drugs in the market is assured. In addition, the integrated health care system means that there is wide access to patient care.
South Korea Psychosis Market is fueled by active investments in the field of neurosciences and the presence of a vibrant biotech community. Public health-insurance schemes cover significant costs related to mental treatment options, and digital health solutions improve patient adherence and monitoring.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Awareness and Early Diagnosis
Rising public awareness about psychotic disorders encourages individuals and families to seek medical attention early, which facilitates timely intervention and reduces disease progression. Educational campaigns and advocacy groups disseminateinformation that demystifies symptoms, prompting healthcare providers to adopt proactive screening practices. Early diagnosis allows clinicians to initiate appropriate pharmacological and psychosocial therapies, improving patient outcomes, and fostering confidence in treatment pathways. This supportive environment fuels demand for diagnostic tools and therapeutic solutions, thereby strengthening market expansion across global healthcare systems.
Adoption of Digital Therapeutics
Inclusion of digital therapies in the treatment of psychosis creates scalable and personalized therapy which is in addition to existing medication. The technology allows for constant monitoring of patients through mobile apps and telepsychiatry services, making it possible to tailor therapy programs. It allows patients to be actively engaged in their own therapy programs, improving their adherence to the program, and reducing the rate of relapses. The increasing understanding by healthcare providers of the role played by these technologies in better therapeutic outcomes results in increased demand for software services.
Stigma Around Mental Health
Continuous stigma associated with mental disorders makes people who suffer from psychotic conditions reluctant to visit health professionals, thus slowing down diagnosis and therapy process. Misunderstandings within the cultural aspect along with the possibility of exclusion from society cause people to conceal their problems, making it hard to speak freely about their early indicators. In addition, health care providers might face a low level of patient participation, making it difficult to implement innovative therapies and conduct clinical trials. This problem prevents growth of market interest towards newly available solutions.
Limited Access to Specialized Care
The shortage of trained mental health clinicians and centers is a problem that limits the efficiency and timeliness of care for psychosis, particularly in underprivileged areas. Due to geographical disparities and limitations in resources, patients are unable to undergo proper evaluation, medical, and psychosocial treatment. In such circumstances, people will undergo fragmented treatment, resulting in less efficient treatment and an increased burden on the disease. The gap in the system prevents the growth of the market due to a limited need for innovative treatments.
Request Free Customization of this report to help us to meet your business objectives.
The competition of the global psychosis market is characterized by quick funding rounds and collaborations to facilitate technology adoption in psychosis management. Funding rounds help firms to improve their AI-assisted diagnostic capabilities, whereas collaborations with health providers and insurance firms ensure rapid reach out to patients to incorporate digital therapeutics and telepsychiatry into their routine treatments.
AI-driven Diagnostic Tools: Integration of artificial intelligence within the clinical practice workflow has been revolutionizing the process of early detection of psychotic conditions. Through machine learning techniques that assess speech and facial cues as well as data from electronic medical records, symptoms that indicate the onset of such disorders can be picked up automatically. Risk levels of patients can therefore be communicated to clinicians in real time, allowing preventive action to take place before full blown episodes occur.
Telepsychiatry Expansion into Rural Areas: The quick adaptation to use of video technology and data communication is bringing the treatment of psychosis closer together despite geographic differences. Now doctors are doing their assessment, medication reviews, and therapy remotely, which means less travel for people who live farther away from specialist clinics. With this approach, there is better care continuity, greater involvement of families, and even crisis interventions due to special video monitoring capabilities. With the improvement in reimbursement models and the expansion of broadband networks, telepsychiatry will become an essential part of mental health care.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the drivers behind the global psychosis market include growing awareness and early diagnosis, thereby driving demand for drugs and diagnostics; and use of digital therapeutic, serving as another driver owing to its ability to provide personalized, remote treatment and enhance patient compliance. The barriers for the market include social stigma associated with mental disorders, which dissuades people from getting help on time. North America leads the market due to its well-developed healthcare system and fast adoption of innovative treatments. In terms of the products, the market is led by atypical antipsychotics owing to their wide-spectrum of action and improved safety.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 12.59 Billion |
| Market size value in 2033 | USD 21.82 Billion |
| Growth Rate | 6.3% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Psychosis Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Psychosis Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Psychosis Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Psychosis Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Psychosis Market size was valued at USD 12.59 Billion in 2024 and is poised to grow from USD 13.38 Billion in 2025 to USD 21.82 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).
The competitive landscape is shaped by rapid capital inflows and strategic collaborations that accelerate technology adoption in psychosis care. Companies are leveraging large funding rounds to enhance AI‑driven diagnostics, while partnerships with health systems and insurers enable rapid patient‑reach, creating a race to integrate digital therapeutics and telepsychiatry into standard treatment pathways. 'Johnson & Johnson (Janssen)', 'Otsuka Pharmaceutical Co. Ltd.', 'Bristol-Myers Squibb', 'Lundbeck A/S', 'Teva Pharmaceutical Industries', 'Eli Lilly and Company', 'Pfizer Inc.', 'Novartis AG', 'AbbVie Inc.', 'AstraZeneca', 'Alkermes plc', 'Intra-Cellular Therapies', 'Biogen Inc.', 'Acadia Pharmaceuticals', 'Sunovion Pharmaceuticals', 'GlaxoSmithKline', 'H. Lundbeck', 'Hikma Pharmaceuticals', 'Dr. Reddy's Laboratories'
Rising public awareness about psychotic disorders encourages individuals and families to seek medical attention early, which facilitates timely intervention and reduces disease progression. Educational campaigns and advocacy groups disseminate information that demystifies symptoms, prompting healthcare providers to adopt proactive screening practices. Early diagnosis allows clinicians to initiate appropriate pharmacological and psychosocial therapies, improving patient outcomes and fostering confidence in treatment pathways. This supportive environment fuels demand for diagnostic tools and therapeutic solutions, thereby strengthening market expansion across global healthcare systems.
Ai-Driven Diagnostic Tools: The integration of artificial intelligence into clinical workflows is reshaping early detection of psychotic disorders. Machine‑learning algorithms analyze speech patterns, facial expressions, and electronic health records to flag subtle symptom emergence. Clinicians receive real‑time risk scores, enabling proactive interventions before full episode development. This technology reduces diagnostic latency, personalizes treatment pathways, and supports continuous monitoring in community settings, thereby expanding access to precision mental health care and fostering collaborative decision‑making across multidisciplinary teams and improving long‑term patient outcomes significantly globally.
Why does North America Dominate the Global Psychosis Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
